Today: 29 June 2026
Browse Category

NASDAQ:PEN 15 January 2026 - 30 January 2026

Boston Scientific stock price climbs as Penumbra deal stays in focus ahead of Feb. 4 earnings

Boston Scientific stock price climbs as Penumbra deal stays in focus ahead of Feb. 4 earnings

Boston Scientific shares rose 1.7% to $93.87 Friday afternoon, outpacing a broader market decline. The move comes ahead of the company’s Feb. 4 earnings report and conference call, its first since announcing a $14.5 billion deal to acquire Penumbra. Investors are watching for details on the acquisition’s impact and the 2026 outlook.
30 January 2026
···
Boston Scientific (BSX) stock falls again as traders digest $14.5 billion Penumbra buy

Boston Scientific (BSX) stock falls again as traders digest $14.5 billion Penumbra buy

Boston Scientific shares fell 1.8% to $88.44 Friday after its $14.5 billion deal to buy Penumbra, while Penumbra rose 0.3% to $351.62. Boston will fund most of the purchase with cash and new debt, expecting a $0.06–$0.08 hit to adjusted EPS in the first year. Penumbra shareholders can choose cash or Boston stock. Deal filings and Boston’s earnings call are set for February 4.
16 January 2026
··
Penumbra stock pops after Boston Scientific’s $14.5 billion buyout — what PEN investors watch next

Penumbra stock pops after Boston Scientific’s $14.5 billion buyout — what PEN investors watch next

Penumbra shares jumped 11.8% to $350.49 in after-hours trading Thursday after Boston Scientific announced a $14.5 billion cash-and-stock acquisition valuing Penumbra at $374 per share. The deal requires Penumbra shareholder approval and antitrust clearance. Penumbra posted preliminary Q4 revenue growth of over 21% year-over-year. Traders focused on the deal spread and closing risks.
15 January 2026
··
Boston Scientific’s $14.5B Penumbra buy: $374-a-share deal lifts PEN stock before the open

Boston Scientific’s $14.5B Penumbra buy: $374-a-share deal lifts PEN stock before the open

Boston Scientific will acquire Penumbra for about $14.5 billion, offering $374 per share in cash and stock. Penumbra shares rose more than 13% premarket, with the bid representing a 19.3% premium to the previous close. The deal expands Boston Scientific’s reach in catheter-based clot removal and neurovascular devices. Penumbra CEO Adam Elsesser will join Boston Scientific’s board.
15 January 2026
··

Stock Market Today

  • Singular Health Group Applies for Quotation of Additional ASX Shares
    June 28, 2026, 8:02 PM EDT. Singular Health Group Ltd has applied for the quotation of 2,571,222 new ordinary fully paid shares on the Australian Securities Exchange (ASX). This move aims to expand the company's market presence and increase liquidity. The application signifies the firm's intent to raise capital or satisfy existing commitments through share issuance. Investors will monitor the impact on share supply and potential dilution. The announcement reflects Singular Health's ongoing efforts to support its growth and operational strategies.

Latest articles

Trump-era loan caps could open door for private lenders in grad school market

Trump-era loan caps could open door for private lenders in grad school market

29 June 2026
July 1 federal loan caps slash Grad PLUS access, forcing many graduate and professional students to seek private loans; Sallie Mae projects up to 70% origination growth over several years, while SoFi reports record student-loan volume—investors now face a real-time test of how much demand shifts to private lenders as federal limits hit.
IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Go toTop